

ShareSoc

UK Individual Shareholders Society

5 Liberty Square, Kings Hill,
West Malling, ME19 4AU
Phone: 0333-200-1595
Web: www.sharesoc.org

SHARESOC GROWTH COMPANY SEMINAR

STOCKOPEDIA FINANCIAL ANALYSIS REPORTS ON PRESENTING COMPANIES

(Don't forget ShareSoc subscribing members can get a discount off the Stockopedia service).

Important Note: These reports do not necessarily reflect the latest changes in the financial position of the companies, for example any recent fund raisings, but are primarily based on the last annual financial statements and future forecasts.

Copies of the Powerpoint presentations given by presenters at these seminars are normally added to our website, here: <https://www.sharesoc.org/seminar/> soon after the Seminar, and are available to logged in full members of ShareSoc.

Use the page below and overleaf to take notes on the presentations.

ShareSoc Investment Warning - Company Presentations

No warranty is given by ShareSoc as to the reliability, accuracy or completeness of the information provided in presentations to investors by companies or by ShareSoc representatives in seminars organised or sponsored by ShareSoc. The information given in those seminars is provided for information purposes only and does not constitute investment, legal, tax or other advice or any recommendation to buy, or sell or otherwise transact in the shares of the companies presenting. Prospective investors should take appropriate professional advice before making any investment decision, or undertake their own further research. You are reminded that investment in the stock market carries substantial risks and share prices can go down as well as up. Past performance is not necessarily an indication of future performance.

Bioventix

BVXP  4210p ▲ 5.0 0.1%Adventurous, Small Cap, **Falling Star**

Market Cap

£219.3m

Quality

99

Enterprise Value

£211.2m

Value

15

Revenue

£10.3m

Momentum

▼ 47

Market Cap Rank

728th / 1805

StockRank™

56

Zoom 1m 3m 6m YTD 1y 2y 3y 5y All



Momentum

Relative Strength (%)

1m +4.5%

3m +3.7%

1yr +66.4%

Volume Change (%)

10d v 3m +150.7%

Price vs... (%)

52w High -6.4%

50d MA +2.02%

200d MA +4.99%

Growth & Value

12m Forecast Rolling

PE Ratio (ttm) 30.5

PEG Ratio (ttm) n/a

EPS Growth (ttm) 23.0 %

Dividend Yield (ttm) 2.09 %

Valuation (ttm)

Price to Book Value 17.5

Price to Tang. Book 17.5

Price to Free Cashflow 29.9

Price to Sales 21.3

EV to EBITDA 26.0

Quality


Return on Capital 65.1 %

Return on Equity 61.7 %

Operating Margin 79.4 %

Health Trend Piotroski F-Score

8



Bankruptcy Risk Altman Z2-Score

308



Earnings Manipulation Risk

High

Magic Formula Score

537 85% A-



Other Ratios

Leverage (ttm)	total	-intang	+pension
Gross Gearing	%		
Net Gearing	%	-64.5	-64.5
Cash / Assets	%	60.7	60.7

Liquidity (ttm)	Efficiency (ttm)
Curr. Ratio	16.4
Quick Ratio	16.1
Interest Cov.	100.0
Asset Turnover	0.85
Rec's Turnover	4.75
Stock Turnover	3.39

Recent History

Latest interim period (ended 30th Jun '20) vs. prior year

Sales Growth 2.50 %

EPS Growth 17.1 %

3yr Compound Annual Growth Rate

Sales Growth 12.5 %

EPS Growth 13.4 %

DPS Growth 19.9 %

Margin of Safety (beta)

Broker Target	-11%
Relative to Sector	-11%
Graham Formula	
Stability Value (EPV)	-77%

Screens Passed 1



BVXP qualifies for **Dividend Achievers** Screen (in Income Investing).

[View Screen](#) · [View Checklist](#)

Financial Summary

Balance Sheet · Income Statement · Cashflow

Year End 30th Jun		2015	2016	2017	2018	2019	2020	2021E	2022E	CAGR / Avg
Revenue	£m	4.33	5.52	7.25	8.75	9.29	10.3	11.1		+18.9%
Operating Profit	£m	3.10	4.21	5.72	6.83	6.93	8.18			+21.4%
Net Profit	£m	2.56	3.49	4.92	5.66	5.86	7.20	7.00		+23.0%
EPS Reported	p	49.8	68.0	94.7	108.3	112.1	137.9			+22.6%
EPS Normalised	p	59.7	81.8	94.7	108.3	112.1	137.9	136.8		+18.2%
EPS Growth	%	+19.7	+37.0	+15.7	+14.4	+3.5	+23.0	-0.82		
PE Ratio	x						30.5	30.8	n/a	
PEG	x						n/a	n/a	n/a	

Profitability

Operating Margin	%	71.5	76.2	78.9	78.1	74.6	79.4			+76.4%
ROA	%		44.6	51.4	50.9	49.9	57.8			
ROCE	%	46.9	51.1	56.3	61.9	63.8	65.1			+57.5%
ROE	%		47.2	53.6	53.5	53.7	61.7			+54.0%

Cashflow

Op. Cashflow ps	p	41.8	62.7	76.1	113.3	112.4	147.1			+28.6%
Capex ps	p	2.21	0.41	0.42	2.06	1.62	6.50			+24.0%
Free Cashflow ps	p	39.5	62.3	75.7	111.2	110.8	140.6			+28.9%

Dividends


Last ex-div: 29th Oct, paid: 13th Nov [more...](#)

Dividend ps	p	32.6	42.5	51.0	61.0	73.0	88.0	98.0		+22.0%
Dividend Growth	%	+35.8	+30.4	+20.0	+19.6	+19.7	+20.5	+11.4		
Dividend Yield	%						2.09	2.33		
Dividend Cover	x	1.53	1.60	1.86	1.78	1.54	1.57	1.40		

Balance Sheet


Cash etc	£m	4.13	5.38	6.17	6.99	6.54	8.08			+14.4%
Working Capital	£m	6.12	7.71	9.52	10.2	9.95	11.2			+12.9%
Net Fixed Assets	£m	0.49	0.51	0.64	0.79	0.90	1.33			+22.2%
Net Debt	£m	-4.13	-5.38	-6.17	-6.99	-6.54	-8.08			
Book Value	£m	6.58	8.21	10.1	11.0	10.8	12.5			+13.7%
Average Shares	m	5.14	5.14	5.20	5.23	5.23	5.22			+0.3%
Book Value ps	p	130.4	162.5	197.4	214.3	210.5	240.4			+13.0%

Graphical History Current Fiscal Year 2021



Broker Forecasts				30th Jun 2021			30th Jun 2022		
Price Target: 37.5 (-10.91% below Price)				Net Profit	EPS	DPS	Net Profit	EPS	DPS
Est. Long Term Growth Rate: n/a				(£)	(p)	(p)	(£)	(p)	(p)
Consensus Estimate				7.00m	136.8	98.0	-	-	-
1m Change				-	-	-	-	-	-
3m Change				-	-	-	-	-	-

Broker Consensus Trend



Profile Summary



Bioventix PLC is a United Kingdom-based biotechnology company. The principal activity of the Company is the development and supply of antibodies. The Company specializes in the development of sheep monoclonal antibodies (SMAs) for use in immunodiagnostics focusing on the areas of clinical diagnostics and drugs of abuse testing. The Company's non-vitamin D business consists of antibodies, NT proBNP (heart failure), testosterone, Free Triiodothyronine (FT3) (thyroid hormone), estradiol, and various drugs, such as tetrahydrocannabinol (THC)/cannabis, and progesterone. The Company offers products for indications, such as thyroid, fertility, oncology, cardiac, vitamin D, drug of abuse, infectious disease and miscellaneous. Its sheep hybridoma technology produces cell lines that secrete SMAs. The Company offers a panel of SMAs to 25-OH D and has various 25-OH D2 and 25-OH D3 specific antibodies. It sells its products through direct sales and through distributors.

Directors: [P. Harrison](#) (CEO), [Ian Nicholson](#) (NEC) 55, [Kim Tan](#) (DRC) 55, [T. Turner](#) (DRC), [Nick McCooke](#) (NED), [Bruce Hiscock](#) (CFO) 61,

No. of Employees: 16

No. of Shareholders: n/a

Last Annual	June 30th, 2020	Sector	Healthcare
Last Interim	June 30th, 2020	Industry	Biotechnology & Medical Research
Incorporated	October 7, 2003	Index	FTSE Aim All Share , FTSE Aim 100 ,
Public Since	April 29, 2014	Exchange	London Stock Exchange (AIM)
Shares in Issue	5,209,333	Eligible for	an ISA? a SIPP?
Free Float	4.26m (81.7%)		




Address 7 Romans Business Park East Street, FARNHAM, GU9 7SX, United Kingdom

Web <http://www.bioventix.com/>

Phone +44 1252 728001

Contact ()

Auditors James Cowper Kreston

BVXP Share Price Quote						BVXP Share Price Performance		
BVXP Share Price		Day's Change		Volume	Bid - Ask	Low - High	Spread	
GBP		▲ 5.0 0.1%		2,872	4,170.0 - 4,250.0	0.0 - 0.0	190bps	
4210p				Avg Vol (3m) 3,403	Open - Close 4,205.0 - 4,210.0	12m Range 2,680.0 - 4,500.0	Beta 0.38	
Traded 4:22pm · Minimum 15 min delayed · NMS: 0.200k								

Latest BVXP News Announcements (delayed)

[More »](#)

Mon 7:30am	BRIEF-Bioventix FY Profit Before Tax Up 18%
Mon 7:00am	Bioventix Plc: Results for the year ended 30 June 2020
20th Aug	Bioventix Plc: Holding(s) in Company
8th Jul	Bioventix Plc: Issue of Equity
2nd Jul	Bioventix Plc: Appointment of CFO

Upcoming BVXP Events

Thursday 29th October, 2020

Dividend For BVXP.L - 53.0000 GBX

Thursday 29th October, 2020

Dividend For BVXP.L - 52.0000 GBX

Recent ↓

Industry Peer Group

	Shield Therapeutic...	☐
	Compare vs BVXP	
	4D Pharma	☐
	Compare vs BVXP	
	Open Orphan	☐
	Compare vs BVXP	
	Verona Pharma	☐
	Compare vs BVXP	
	MaxCyte Inc	☐
	Compare vs BVXP	
	Synairgen	☐
	Compare vs BVXP	
	Silence Therapeuti...	☐
	Compare vs BVXP	
	Tiziana Life Scien...	☐
	Compare vs BVXP	

[Healthcare](#)
[Biotechnology & Medical Research](#)